Thrombosis News and Research

Latest Thrombosis News and Research

First study to examine soda's effect on stroke risk

Researchers from Cleveland Clinic's Wellness Institute and Harvard University have found that greater consumption of sugar-sweetened and low-calorie sodas is associated with a higher risk of stroke. Conversely, consumption of caffeinated or decaffeinated coffee was associated with a lower risk.

21 Apr 2012

Perivascular fat tissue may influence onset of atherosclerosis

Researchers at UC have confirmed that fat surrounding the outside of arteries in humans-particularly the left coronary artery-may influence the onset of coronary artery disease, or atherosclerosis, which is the leading cause of death in the U.S.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

Depression may increase risk of peripheral artery disease

Depression may be associated with an increased risk of arterial narrowing in the legs and pelvis, a condition known as peripheral artery disease (PAD), according to research presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions in Chicago.

21 Apr 2012

HDAC9 gene can lead to obesity-induced body fat dysfunction

Cardiac researchers at the University of Cincinnati (UC) have found that a certain cellular pathway is linked to obesity-related disorders, like diabetes, heart disease and fatty liver disease.

20 Apr 2012

AcelRx commences dosing in second ARX-01 Phase 3 clinical trial for acute post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application for the Sufentanil NanoTab PCA System, ARX-01.

12 Apr 2012

Japanese MHLW approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

9 Apr 2012

Researchers question wisdom of blocking DP1 in patients prone to cardiovascular disease

Niacin, or vitamin B3, is the one approved drug that elevates "good" cholesterol (high density lipoprotein, HDL) while depressing "bad" cholesterol (low density lipoprotein , LDL), and has thereby attracted much attention from patients and physicians. Niacin keeps fat from breaking down, and so obstructs the availability of LDL building blocks.

9 Apr 2012

VasoNova receives BSI CE certification for Arrow VPS system

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has announced that its VasoNova Inc. subsidiary has been issued CE certification from its notified body, the British Standards Institution (BSI), to market the company's Arrow VPS system to the European Union.

9 Apr 2012

Peripheral IV catheter effective alternative to central lines

A new study concludes that the POWERWAND peripheral IV (PIV) catheter is an effective alternative to central lines and standard PIV's, achieving unprecedented levels of success in patients requiring longer-term IV therapy.

5 Apr 2012

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

4 Apr 2012

Studies use three genes to reprogram fibroblasts into myocytes

The latest research developments to reprogram scar tissue resulting from myocardial infarction (MI) into viable heart muscle cells, were presented at the Frontiers in CardioVascular Biology (FCVB) 2012 meeting, held 30 March to 1 April at the South Kensington Campus of Imperial College in London.

2 Apr 2012

Starvation during childhood may increase risk of heart complications

Russians born during the Leningrad Siege in World War II, which was responsible for some of the greatest losses of civilian life in history, are giving scientists new strategies to identify people who experienced intrauterine growth restriction (IUGR) and starvation during childhood at greatest risk of developing long term heart complications.

31 Mar 2012

Hyperinsulinemia itself not a cause of atherosclerosis

A number of studies have shown that excess insulin circulating in the bloodstream is a major independent risk factor for cardiovascular disease. However, a new study from Joslin Diabetes Center finds that this condition, called hyperinsulinemia, is itself not a cause of atherosclerosis.

28 Mar 2012

Mount Sinai researchers present 86 abstracts and plenary sessions at ACC meeting

Mount Sinai School of Medicine researchers presented 86 abstracts and plenary sessions at the American College of Cardiology's (ACC) 61st Annual Scientific Session, including ground-breaking research on aggressive statin therapy, the prevalence of unrecognized cardiovascular disease symptoms in women, and morbidity associated with non-adherence to medication after stent implantation. The meeting took place March 23-27, 2012 in Chicago.

28 Mar 2012

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

The Cardiovascular Research Foundation (CRF) today announced the initiation of the HORIZONS-AMI II randomized trial, evaluating Promus Element platinum-chromium everolimus-eluting stents versus Omega bare-metal stents in patients with heart attack undergoing primary angioplasty with bivalirudin anticoagulation.

28 Mar 2012

Lower dose of thrombolytics can treat moderate pulmonary embolism

Pulmonary embolism -- the sudden blockage of an artery in the lung -- is estimated to cause over 100,000 deaths each year in the U.S. Although thrombolytics, or "clot-buster" drugs, are currently reserved to treat only the most severe cases of pulmonary embolism, new data suggest that when used at lower doses, these drugs are also safe and effective for more common, moderate cases of pulmonary embolism, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

28 Mar 2012

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF (Atrial fibrillation) patients, and as additional therapy to conventional antiplatelet therapy in ACS (Acute coronary syndrome) patients.

27 Mar 2012

Minimally invasive treatments re-establish blood flow in people with chronic DVT

Interventional radiology treatments re-establish blood flow in people with chronic deep vein thrombosis (DVT), reducing disabling symptoms and improving the quality of life for those afflicted with post-thrombotic syndrome—an under-recognized but frequent long-term complication of DVT.

27 Mar 2012

Rivaroxaban safer, effective than standard therapy in treating PE

A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism - a blockage of lung blood vessels usually caused by a clot - and showed comparable efficacy, according to data from the EINSTEIN-PE trial presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Thrombosis News and Research

Latest Thrombosis News and Research

First study to examine soda's effect on stroke risk

Perivascular fat tissue may influence onset of atherosclerosis

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Depression may increase risk of peripheral artery disease

HDAC9 gene can lead to obesity-induced body fat dysfunction

AcelRx commences dosing in second ARX-01 Phase 3 clinical trial for acute post-operative pain

Japanese MHLW approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Researchers question wisdom of blocking DP1 in patients prone to cardiovascular disease

VasoNova receives BSI CE certification for Arrow VPS system

Peripheral IV catheter effective alternative to central lines

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

Studies use three genes to reprogram fibroblasts into myocytes

Starvation during childhood may increase risk of heart complications

Hyperinsulinemia itself not a cause of atherosclerosis

Mount Sinai researchers present 86 abstracts and plenary sessions at ACC meeting

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

Lower dose of thrombolytics can treat moderate pulmonary embolism

Rivaroxaban found safe and effective in pulmonary embolism

Minimally invasive treatments re-establish blood flow in people with chronic DVT

Rivaroxaban safer, effective than standard therapy in treating PE

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Thrombosis News and Research

Latest Thrombosis News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in